Janssen discontinued development of a CD20/CD19 CAR T therapy, prizloncabtagene autoleucel (C-CAR039), and Abelzeta Pharma regained rights to the program. Janssen’s decision reverses the earlier out-licensing arrangement, with Abelzeta holding global rights outside China. The update matters because it signals where large sponsors are concentrating resources—often shifting away from certain CAR T constructs after efficacy, safety, manufacturing, or commercial trajectory assessments. For Abelzeta, the regained asset reopens development options, including potential re-trial design or combination exploration. Investors and clinicians will watch whether Abelzeta can advance the program with a clearer pathway, particularly given the crowded competitive landscape for CD20-directed and bispecific CAR approaches.